Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017036852) ERBB4 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF DYSTROPHIN-ASSOCIATED DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/036852 International Application No.: PCT/EP2016/069877
Publication Date: 09.03.2017 International Filing Date: 23.08.2016
IPC:
A61K 38/18 (2006.01) ,A61P 21/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
18
Growth factors; Growth regulators
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21
Drugs for disorders of the muscular or neuromuscular system
Applicants:
GAJENDRAN, Nadesan [BE/CH]; CH
Inventors:
GAJENDRAN, Nadesan; CH
Agent:
AMIRSEHHI, Ramin; NL
DEN HARTOG, Jeroen; NL
PFISTER, Matthias; NL
HAARTSEN, Jan Pieter; NL
OWEN, David; NL
DERKS, Wilhelmus; NL
DE BAAT, Michiel Anton; NL
PIERCE, Christopher; NL
ELKENBRACHT, Johan; NL
Priority Data:
15183607.903.09.2015EP
Title (EN) ERBB4 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF DYSTROPHIN-ASSOCIATED DISEASES
(FR) MODULATEURS DU RÉCEPTEUR ERBB 4 POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES ASSOCIÉES À LA DYSTROPHINE
Abstract:
(EN) The present invention relates to novel means for regulating dystrophin expression for treating diseases in a subject, and more particularly to novel means for regulating dystrophin expression for treating dystrophin associated diseases via modulators of ErbB4 receptor and/or via free ErbB4 intracellular domain.
(FR) La présente invention concerne de nouveaux moyens de régulation de l'expression de la dystrophine pour le traitement de maladies chez un sujet, et plus particulièrement de nouveaux moyens de régulation de l'expression de la dystrophine pour le traitement de maladies associées à la dystrophine, par l'intermédiaire de modulateurs du récepteur ErbB 4 et/ou par l'intermédiaire du domaine intracellulaire libre d'ErbB4.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Licensing availability request The applicant has requested the International Bureau to indicate the availability for licensing purposes of the invention(s) claimed in this international application